Efficacy of human placenta hydrolyzate in the treatment of patients with metabolic associated fatty liver disease at the stage of fibrosis (pilot study)
- 作者: Vinnitskaya E.1, Sandler Y.1, Saliev K.1, Ivanov A.1, Sbikina E.1, Khaymenova T.1, Bordin D.1,2,3
-
隶属关系:
- Loginov Moscow Clinical Scientific Center
- Russian University of Medicine
- Tver State Medical University
- 期: 卷 96, 编号 2 (2024)
- 页面: 107-116
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/254706
- DOI: https://doi.org/10.26442/00403660.2024.02.202582
- ID: 254706
如何引用文章
全文:
详细
Background. Despite active research, drug treatment options for metabolic associated fatty liver disease (MAFLD) are limited, and there are no currently approved drugs for patients with MAFLD. Treatment of patients at risk of developing non-alcoholic steatohepatitis and progressive liver fibrosis (LF) is of particular relevance, since they determine the clinical outcomes of the disease.
Aim. To evaluate the clinical efficacy of complex polypeptide drug (CPD), human placenta hydrolyzate, containing low molecular weight regulatory peptides, amino acids, vitamins, macro- and microelements in patients with MAFLD at the LF stage.
Materials and methods. A single-center, placebo-controlled pilot study. Patients with MAFLD at LF stage 1≤F≤3 according to METAVIR were included (n=10, of which 8 were women, median age was 55 years old). Patients were randomized into 2 groups: 5 people received CPD therapy for 12 weeks (intravenous infusion of 6 ml 2 times a week); another 5 people initially received placebo x 2 times a week (12 weeks), with transfer to the open phase for CPD therapy in the same regimen. The dynamics laboratory and instrumental data was assessed, as well as determine the presence of fibrosis by non-invasive tests – measurement of liver stiffness by transient elastography and use of serum biomarker (SM) by FibroTest and detection of steatosis with controlled attenuation parameter for transient elastography and SM by SteatoTest. The quality of life of patients was assessed using questionnaire SF-36 and well-being via Visual Analogue Scale. Statistical processing of the material was carried out using the methods of nonparametric analysis, using the Statistica 13.3 software.
Results. Patients in the CPD group compared with the baseline data and with the placebo group showed a statistically significant improvement: 1) transaminases (ALT, AST), lipid profile indicators (cholesterol), ferritin; 2) indicators of LF, based on a decrease in liver stiffness by transient elastography and SM of Fibrotest, as well as the degree of steatosis based on controlled attenuation parameter and SM of Steatotest; 3) in well-being and quality of life (according to testing: SF-36 physical, mental well-being and general condition of the VAS). CPD was well tolerated, no side effects were noted.
Conclusion. In patients with MAFLD during CPD therapy, a decrease in the level of liver enzymes was noted, as well as in LF and liver steatosis according to noninvasive methods. Randomized controlled trials are required to confirm these findings.
作者简介
Elena Vinnitskaya
Loginov Moscow Clinical Scientific Center
Email: y.sandler@mknc.ru
ORCID iD: 0000-0002-0344-8375
д-р мед. наук, зав. отд. гепатологии
俄罗斯联邦, MoscowYuliay Sandler
Loginov Moscow Clinical Scientific Center
编辑信件的主要联系方式.
Email: y.sandler@mknc.ru
канд. мед. наук, ст. науч. сотр. научно-исследовательского отд. гепатологии
俄罗斯联邦, MoscowKirill Saliev
Loginov Moscow Clinical Scientific Center
Email: y.sandler@mknc.ru
ORCID iD: 0000-0002-4581-7052
мл. науч. сотр. отд. гепатологии
俄罗斯联邦, MoscowAnton Ivanov
Loginov Moscow Clinical Scientific Center
Email: y.sandler@mknc.ru
ORCID iD: 0000-0002-3173-4221
мл. науч. сотр. отд. гепатологии
俄罗斯联邦, MoscowEvgenia Sbikina
Loginov Moscow Clinical Scientific Center
Email: y.sandler@mknc.ru
ORCID iD: 0000-0003-2195-9643
канд. мед. наук, науч. сотр. отд. гепатологии
俄罗斯联邦, MoscowTatyana Khaymenova
Loginov Moscow Clinical Scientific Center
Email: y.sandler@mknc.ru
ORCID iD: 0000-0002-4599-4040
канд. мед. наук, зав. отд-нием заболеваний печени
俄罗斯联邦, MoscowDmitry Bordin
Loginov Moscow Clinical Scientific Center; Russian University of Medicine; Tver State Medical University
Email: y.sandler@mknc.ru
ORCID iD: 0000-0003-2815-3992
д-р мед. наук, зав. отд. патологии поджелудочной железы, желчных путей и верхних отделов пищеварительного тракта ГБУЗ «МКНЦ им. А.С. Логинова», проф. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «Российский университет медицины», проф. каф. общей врачебной практики и семейной медицины фак-та последипломного образования ФГБОУ ВО «Тверской ГМУ»
俄罗斯联邦, Moscow; Moscow; Tver参考
- Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl.):S47-64. doi: 10.1016/j.jhep.2014.12.012
- Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut. 2021;70(8):1570-9. doi: 10.1136/gutjnl-2020-323202
- Винницкая Е.В., Сандлер Ю.Г., Бордин Д.С. Новая парадигма неалкогольной жировой болезни печени: фенотипическое многообразие метаболически ассоциированной жировой болезни печени. Эффективная фармакотерапия. 2020;16(24):54-63 [Vinnitskaya YeV, Sandler YuG, Bordin DS. The New Paradigm of Non-Alcoholic Fatty Liver Disease: Phenotypic Diversity of Metabolically Associated Fatty Liver Disease. Effektivnaia farmakoterapiia. 2020;16(24):54-63 (in Russian)]. doi: 10.33978/2307-3586-2020-16-24-54-63
- Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-56. doi: 10.1016/j.jhep.2023.06.003
- Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103(1):22-7. doi: 10.1097/TP.0000000000002484
- EASL–EASD–EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121-40. doi: 10.1007/s00125-016-3902-y
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. doi: 10.1002/hep.29367
- Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68(1):349-60. doi: 10.1002/hep.29721
- Sanyal AJ, Friedman SL, McCullough AJ, et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61(4):1392-405. doi: 10.1002/hep.27678
- Dyson JK, McPherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol. 2013;66(12):1033-45. doi: 10.1136/jclinpath-2013-201620
- Festi D, Schiumerini R, Scaioli E, Colecchia A. Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease – authors' reply. Aliment Pharmacol Ther. 2013;37(6):656-7. doi: 10.1111/apt.12228
- Маевская М.В., Котовская Ю.В., Ивашкин В.Т., и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216-53 [Maevskaya MV, Kotovskaya YuV, Ivashkin VT, et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(2):216-53. doi: 10.26442/00403660.2022.02.201363
- Sanal MG. Biomarkers in nonalcoholic fatty liver disease – the emperor has no clothes? World J Gastroenterol. 2015;21(11):3223-31. doi: 10.3748/wjg.v21.i11.3223
- Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156(5):1264-81.e4. doi: 10.1053/j.gastro.2018.12.036.
- Lassailly G, Caiazzo R, Hollebecque A, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol. 2011;23(6):499-506. doi: 10.1097/meg.0b013e3283464111
- Винницкая Е.В., Сандлер Ю.Г., Кейян В.А., и др. Применение современных методов диагностики фиброза и стеатоза печени в диагностике хронических заболеваний печени в условиях стационарных и поликлинических учреждений: методические рекомендации. М. 2019 [Vinnitskaia EV, Sandler IuG, Keiian VA, et al. Primenenie sovremennykh metodov diagnostiki fibroza i steatoza pecheni v diagnostike khronicheskikh zabolevanii pecheni v usloviiakh statsionarnykh i poliklinicheskikh uchrezhdenii: metodicheskie rekomendatsii. Moscow. 2019 (in Russian)].
- Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2(2):100067. doi: 10.1016/j.jhepr.2020.100067
- Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184-96. doi: 10.1016/s0140-6736(19)33041-7
- Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020;72(3):892-905. doi: 10.1002/hep.31108
- AURORA: phase 3 study for the efficacy and safety of CVC for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT03028740. Accessed: 28.09.2023.
- Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-24. doi: 10.1056/nejmoa2028395
- Неалкогольная жировая болезнь печени у взрослых: клинические рекомендации. Режим доступа: https://cr.minzdrav.gov.ru/schema/748_1. Ссылка активна на 12.10.2023 [Nealkogol'naia zhirovaia bolezn' pecheni u vzroslykh: klinicheskie rekomendatsii. Available at: https://cr.minzdrav.gov.ru/schema/748_1. Accessed: 12.10.2023 (in Russian)].
- Тран В.Т., Торшин И.Ю., Громова О.А. Открытое контролируемое исследование эффективности и безопасности применения Лаеннека для улучшения функции печени у пациентов с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2023;(8):48-56 [Tran VT, Torshin IYu, Gromova OA. An open-label, controlled trial of the efficacy and safety of Laennec to improve liver function in patients with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2023;(8):48-56 (in Russian)]. doi: 10.31146/1682-8658-ecg-216-8-48-56
- Пирогова И.Ю., Неуймина Т.В., Сучкова О.В., и др. Препарат Лаеннек (гидролизат плаценты человека) в монотерапии стеатогепатитов смешанной этиологии. Экспериментальная и клиническая гастроэнтерология. 2023;(8):37-47 [Pirogova IYu, Neuimina TV, Suchkova OV, et al. Laennec (Human placenta hydrolyzate) in monotherapy of mixed etiology of steatohepatitis. Experimental and Clinical Gastroenterology. 2023;(8):37-47 (in Russian)]. doi: 10.31146/1682-8658-ecg-216-8-37-47
- Торшин И.Ю., Громова О.А., Тихонова О.В., Згода В.Г. Гепатопротекторные пептиды препарата Лаеннек. Экспериментальная и клиническая гастроэнтерология. 2022;(7):21-30 [Torshin IYu, Gromova OA, Tikhonova OV, Zgoda VG. Hepatoprotective peptides of the drug Laennec. Experimental and Clinical Gastroenterology. 2022;(7):21-30 (in Russian)]. doi: 10.31146/1682-8658-ecg-203-7-21-30
- Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci. 2016;61(5):1325-36. doi: 10.1007/s10620-015-3977-1
- Larter CZ, Yeh MM, Williams J, et al. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol. 2008;49(3):407-16. doi: 10.1016/j.jhep.2008.03.026
- Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105(8):1067-75. doi: 10.1172/jci8814
- Miyao M, Kotani H, Ishida T, et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. Lab Invest. 2015;95(10):1130-44. doi: 10.1038/labinvest.2015.95
- Yamauchi A, Kamiyoshi A, Koyama T, et al. Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells. Heliyon. 2017;3(9):e00416. doi: 10.1016/j.heliyon.2017.e00416
- Wang G, Yeung CK, Wong WY, et al. Liver Fibrosis Can Be Induced by High Salt Intake through Excess Reactive Oxygen Species (ROS) Production. J Agric Food Chem. 2016;64(7):1610-7. doi: 10.1021/acs.jafc.5b05897
- Chen CP, Tsai PS, Huang CJ. Antiinflammation effect of human placental multipotent mesenchymal stromal cells is mediated by prostaglandin E2 via a myeloid differentiation primary response gene 88-dependent pathway. Anesthesiology. 2012;117(3):568-79. doi: 10.1097/aln.0b013e31826150a9
- Samala N, Desai A, Vilar-Gomez E, et al. Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020;18(13):2980-8.e4. doi: 10.1016/j.cgh.2020.04.046
- Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2009;11(2):136-40. doi: 10.1038/ni.1831
- Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry. 2005;58(3):175-89. doi: 10.1016/j.biopsych.2005.05.001
- Vandanmagsar B, Youm Y-H, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179-88. doi: 10.1038/nm.2279
- Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31(1):105-14. doi: 10.1016/j.bbi.2012.12.008
- Mason DR, Beck PL, Muruve DA. Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. Journal of Innate Immunity. 2012;4(1):16-30. doi: 10.1159/000334247
- Mariathasan S, Newton K, Monack DM, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004;430(6996):213-8. doi: 10.1038/nature02664
- Martinon F, Burns K, Tschopp J. The inflammasome. Mol Cell. 2002;10(2):417-26. doi: 10.1016/s1097-2765(02)00599-3
- Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-32. doi: 10.1016/j.cell.2010.01.040
- Park H-J, Shim H-S, Chung SY, et al. Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats. BMC Complement Altern Med. 2014;14:34. doi: 10.1186/1472-6882-14-34
- Seo J-S, Park J-Y, Choi J, et al. NADPH oxidase mediates depressive behavior induced by chronic stress in mice. J Neurosci. 2012;32(28):9690-9. doi: 10.1523/jneurosci.0794-12.2012
- Patil R, Dhawale K, Gound H, Gadakh R. Protective effect of leaves of murrayakoenigii on reserpine-induced orofacial dyskinesia. Iran J Pharm Res. 2012;11(2):635-41.
- Lenzi J, Rodrigues AF, de Sousa Rós A, et al. Erratum to: Ferulic acid chronic treatment exerts antidepressant-like effect: role of antioxidant defense system. Metab Brain Dis. 2015;30(6):1465. doi: 10.1007/s11011-015-9751-4
- Sacchet C, Mocelin R, Sachett A, et al. Antidepressant-Like and Antioxidant Effects of Plinia trunciflora in Mice. Evid Based Complement Alternat Med. 2015;2015:601503. doi: 10.1155/2015/601503
- Silva MC, de Sousa CNS, Gomes PXL, et al. Evidence for protective effect of lipoic acid and desvenlafaxine on oxidative stress in a model depression in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:142-8. doi: 10.1016/j.pnpbp.2015.08.002
- Yu HC, Wu J, Zhang HX, et al. Antidepressant-like and anti-oxidative efficacy of Campsis grandiflora flower. J Pharm Pharmacol. 2015;67(12):1705-15. doi: 10.1111/jphp.12466
- Chakraborty D, Basu JM, Sen P, et al. Human placental extract offers protection against experimental visceral leishmaniasis: a pilot study for a phase-I clinical trial. Ann Trop Med Parasitol. 2008;102(1):21-38. doi: 10.1179/136485908x252133
- Akyol N, Akpolat N. Effects of intraoperative oxidated regenerated cellulose on wound healing reaction after glaucoma filtration surgery: A comparative study with Interceed and Surgicel. Indian J Ophthalmol. 2008;56(2):109-14. doi: 10.4103/0301-4738.39114
- Kaushal V, Verma K, Manocha S, et al. Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis. Int J Tissue React. 2001;23(3):105-10.
- Mason DR, Beck PL, Muruve DA. Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. J Innate Immun. 2012;4(1):16-30. doi: 10.1159/000334247
- Park H-J, Shim HS, Lee S, et al. Anti-stress effects of human placenta extract: possible involvement of the oxidative stress system in rats. BMC Complement Altern Med. 2018;18(1):149. doi: 10.1186/s12906-018-2193-x